kicked off on Tuesday, with NovoCure Ltd (NASDAQ: NVCR) stock price up 0.34% from the previous day of trading, before settling in for the closing price of $14.61. NVCR’s price has ranged from $10.87 to $24.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 17.16% over the past five years. Meanwhile, its annual earnings per share averaged 29.89%. With a float of $97.51 million, this company’s outstanding shares have now reached $107.08 million.
Let’s look at the performance matrix of the company that is accounted for 1453 employees. In terms of profitability, gross margin is 75.82%, operating margin of -33.65%, and the pretax margin is -25.66%.
NovoCure Ltd (NVCR) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 9.89%, while institutional ownership is 85.79%. The most recent insider transaction that took place on Aug 02 ’24, was worth 13,857. In this transaction Chief Financial Officer of this company sold 688 shares at a rate of $20.14, taking the stock ownership to the 219,179 shares. Before that another transaction happened on Jun 04 ’24, when Company’s Director sold 964 for $23.89, making the entire transaction worth $23,033. This insider now owns 164,833 shares in total.
NovoCure Ltd (NVCR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 29.89% per share during the next fiscal year.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Here are NovoCure Ltd’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.57, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.48 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
NovoCure Ltd (NASDAQ: NVCR) saw its 5-day average volume 0.76 million, a negative change from its year-to-date volume of 1.3 million. As of the previous 9 days, the stock’s Stochastic %D was 14.34%. Additionally, its Average True Range was 0.93.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 4.64%, which indicates a significant decrease from 11.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.19% in the past 14 days, which was lower than the 65.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.76, while its 200-day Moving Average is $16.70. Nevertheless, the first resistance level for the watch stands at $14.94 in the near term. At $15.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.60. If the price goes on to break the first support level at $14.27, it is likely to go to the next support level at $13.89. The third support level lies at $13.61 if the price breaches the second support level.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
With a market capitalization of 1.59 billion, the company has a total of 107,611K Shares Outstanding. Currently, annual sales are 509,340 K while annual income is -207,040 K. The company’s previous quarter sales were 150,360 K while its latest quarter income was -33,380 K.
